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s u m m a r y 
Background: Reactive arthritis, irritable bowel syndrome (IBS), Guillain-Barré syndrome, ulcerative coli- 
tis, and Crohn’s disease may be sequelae of Campylobacter or non-typhoidal Salmonella (NTS) infections. 
Proton pump inhibitors (PPI) and antibiotics may increase the risk of gastrointestinal infections (GII); 
however, their impact on sequelae onset is unclear. We investigated the incidence of sequelae, their as- 
sociation with antibiotics and PPI prescription, and assessed the economic impact on the NHS. 
Methods: Data from the Clinical Practice Research Datalink for patients consulting their GP for Campy- 
lobacter or NTS infection, during 20 0 0–2015, were linked to hospital, mortality, and Index of Multiple 
Deprivation data. We estimated the incidence of sequelae and deaths in the 12 months following GII. We 
conducted logistic regression modelling for the adjusted association with prescriptions. We compared dif- 
ferences in resource use and costs pre- and post-infection amongst patients with and without sequelae. 
Findings: Of 20,471 patients with GII ( Campylobacter 17,838), less than 2% (347) developed sequelae, with 
IBS (268) most common. Amongst Campylobacter patients, those with prescriptions for PPI within 12 
months before and cephalosporins within 7-days before/after infection had elevated risk of IBS (adjusted 
odds ratio [aOR] 2.1, 1.5–2.9) and (aOR 3.6, 1.1–11.7) respectively. Campylobacter sequelae led to ∼ £1.3 
million, (£750,0 0 0, £1.7 million) in additional annual NHS expenditure. 
Interpretation: Sequelae of Campylobacter and NTS infections are rare but associated with increased NHS 
costs. Prior prescription of PPI may be a modifiable risk factor. Incidence of sequelae, healthcare resource 
use and costs are essential parameters for future burden of disease studies. 
© 2020 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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Evidence before this study 
Campylobacter and non-typhoidal Salmonella (NTS) gas- 
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health records, Journal of Infection, https://doi.org/10.1016/j.jinf.2020.05but sequelae including irritable bowel syndrome (IBS), reac- 
tive arthritis (ReA), Guillain Barré syndrome (GBS), ulcera- 
tive colitis (UC), Crohn’s disease (CD) and rheumatoid arthri- 
tis (RA) increase the burden on patients and the health ser- 
vice. Which patient or pathogen factors increase the risk of 
these sequelae remains uncertain. 
In a systematic review of studies reporting the onset of 
ReA ( n = 37), IBS ( n = 5) and GBS ( n = 9) published by our 
group in 2016, the incidence of sequelae varied depending 
on the study size and data source. Studies comprising large 
cohorts of > 10,0 0 0 reported a low incidence of ReA and IBS tion Association. This is an open access article under the CC BY-NC-ND license. 
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fi  ( < 1%), contrasting with outbreak investigation reports (up to 
60%). Scarce (1 study) or weak evidence (6) was found of a 
relation between sequelae and PPI or antibiotics use, respec- 
tively. 
We searched MEDLINE, Embase, and Web of Science from 
the date of the last search of the 2016 review (April 27, 2016) 
up to August 2019, for observational cohort studies and sys- 
tematic reviews and meta-analyses reporting on associations 
of patient-related and pathogen-related factors in the onset 
of sequelae following GII. We used search terms related to 
the exposures "Campylobacter Infections", "Salmonella Infec- 
tions", campylobacter ∗, salmonella ∗ combined with those re- 
lated to sequelae "Guillain-Barré Syndrome", "Inflammatory 
Bowel Diseases", "Irritable Bowel Syndrome", "Arthritis, Reac- 
tive", crohn ∗, colitis ∗, and “IBS”. Our search was not restricted 
by language. We identified one registry study, which demon- 
strated increased risk of IBD following bacterial infection (ad- 
justed odds ratio [aOR]1.6, 95% C.I 1.6–1.7) with risk elevated 
for antimicrobial treatment (aOR 4.2, 95% C.I 3.3–5.3), al- 
though pathogen-specific risk factor estimates were limited. 
The most recent systematic review of post-infectious IBS (PI- 
IBS) identified a study with elevated risk following antibi- 
otic treatment in children only, while a previous review re- 
ported an association with antibiotics regardless of the pop- 
ulation structure. Both reviews agreed on other factors asso- 
ciated with elevated risk of PI-IBS which include, individuals 
who were young, female, had a history of anxiety, depression 
and somatisation. However, one review included studies on 
both prevalence and incidence while the latter only focused 
on prevalence. Moreover, pathogen-specific risk factor esti- 
mates were lacking. Existing evidence for the role of patient- 
related factors on risk of post-infectious sequelae is limited 
by inadequate sample sizes, inconsistent follow-up durations, 
and substantial inter-study heterogeneity. 
Added value of this study 
Using a single large observational cohort of 20,471 pa- 
tients with Campylobacter (17,838) or NTS (2633) infections, 
this study estimated the pathogen-specific incidence of se- 
quelae in England, associated risk factors, and the result- 
ing economic burden on the NHS. Within 12 months post- 
infection, < 2% developed sequelae, with IBS most frequently 
diagnosed (1.1%). Female sex, age < 65 years, previous long- 
term exposure to PPI, use of cephalosporins were associated 
with elevated risk of IBS. Sequelae of Campylobacter led to 
∼£1.3 million (95% C.I £750,0 0 0, £1.7 million) in additional 
NHS expenditure annually, while for NTS it was lower at 
∼£224,0 0 0 (95% C.I £0, £465,0 0 0). Males aged > 65 with pre- 
existing comorbidities accrued the highest costs. 
Implications of all the available evidence 
Despite several industry wide interventions and public 
health campaigns, Campylobacter incidence has remained sta- 
ble, although NTS incidence is declining. These infections still 
pose a considerable burden on healthcare resources. Esti- 
mates of the clinical and economic consequences of sequelae 
are crucial in understanding the burden of these infections 
and can be incorporated into economic evaluation models to 
inform strategies for reducing the burden of these infections. 
Introduction 
Campylobacter spp. is the most common bacterial cause of gas-
trointestinal infection (GII) globally and in the United Kingdom
(UK), while non-typhoidal Salmonella (NTS) is the leading cause of
death amongst bacterial GII pathogens. 1 Despite several industry
wide interventions and public health campaigns, Campylobacter in-Please cite this article as: O.B. Esan, R. Perera and N. McCarthy et a
of campylobacter and non-typhoidal salmonella infections in England, 
health records, Journal of Infection, https://doi.org/10.1016/j.jinf.2020.05idence has remained relatively stable in the last decade and leads
o 80,0 0 0 primary care consultations annually in the UK. 2 , 3 While
TS infections are on the decline but responsible for several multi-
ountry outbreaks of recent. 4 , 5 Although these zoonotic infections
re usually self-limiting intestinal complications of irritable bowel
yndrome (IBS), Crohn’s disease (CD) and ulcerative colitis (UC),
nd extra-intestinal manifestations such as reactive arthritis (ReA),
uillain-Barré Syndrome (GBS), and rheumatoid arthritis (RA) can
ccur. 6 
Drugs which alter gastric pH, such as proton pump inhibitors
PPI) and antibiotics, can increase susceptibility to GII. 7 , 8 A Dutch
ase-control study reported that PPI usage was associated with re-
eated gastroenteritis episodes and risk of ReA following campy-
obacteriosis. 9 However, their overall role in post-infectious seque-
ae is uncertain. 
These GII have high economic implications. According to 2008–
9 UK data from the Intestinal Infectious Disease Study 2 (IID2),
ampylobacter infections cost ∼£50 million annually, 20% of which
s due to direct healthcare costs, but GBS was the only sequela
onsidered in this estimate. 10 Available cost estimates for NTS in-
ections in the UK date back to the 1993–96 IID1 study with an
verall cost of £46.4 million. 11 These estimates do not explore the
nfluence of patients’ characteristics in healthcare resource utili-
ation and associated costs. Exploiting patient-level heterogeneity
an enable efficient allocation of healthcare resources, and provide
argeted prevention strategies. 12 
We aimed to determine the incidence of sequelae of Campy-
obacter and NTS infections; risk factors associated with sequelae
nset; and the resulting impact on the volume, type, and costs of
ealthcare resources in primary and secondary settings in England.
ethods 
tudy design and population 
In this cohort study, we identified patients with a recorded di-
gnosis of Campylobacter or NTS infection in the Clinical Practice
esearch Datalink (CPRD) between 20 0 0–2015 during consultation
ith their General Practitioner (GP) (Appendix Table S1, p2). We
ollowed up individuals from consultation date to the earliest of
ate of death, transfer out of GP practice or end of 2015. All pa-
ients were registered with their GP practice for at least 12 months
efore study entry for adequate measurement of baseline charac-
eristics. Primary care data were linked to patients’ hospital en-
ounters (Hospital Episode Statistics – HES), mortality records (Of-
ce of National Statistics – ONS) and socioeconomic status (Index
f Multiple Deprivation 2010 – IMD-2010). Datasets were linked by
 trusted third party, NHS Digital for the Medicines and Healthcare
roducts Regulatory Agency (MHRA) using the patient’s NHS iden-
ification number, sex, date of birth, and postcode. 13 
CPRD contains anonymised longitudinal data of all primary care
ncounters for over 14 million patients from general practices in
he UK. 14 HES contains hospital encounters in England including
nformation on deaths in the hospital from 1997. 15 ONS death reg-
stration data contain the date and coded cause of death for Eng-
and and Wales from 1998. 12 HES and ONS data are coded using
he International Classification of Diseases (ICD) versions 9 (20 0 0
or ONS only) and 10 (all HES and 2001 onwards for ONS). The
tudy was approved by the MHRA Independent Scientific Advisory
ommittee (16_112). 
rocedures 
For each patient, an index date was defined as the date of con-
ultation for diagnosis of either Campylobacter or NTS. Only the
rst record was retained for recurrent episodes occurring withinl., Incidence, risk factors, and health service burden of sequelae 
20 0 0–2015: A retrospective cohort study using linked electronic 
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p month of the first episode. Patients with multiple infections
ecorded on the same date and those with a previous history of
he conditions of interest were excluded. We extracted data on
ge, sex, socio-economic status (SES) quintile, smoking status and
harlson Comorbidity Index (CCI). 
We considered the number of prescriptions for quinolones,
acrolides and cephalosporins within 7-days before and after the
ndex date. The period before diagnosis was included as clinicians
ay prescribe broad-spectrum antibiotics before the aetiology is
onfirmed. For PPI, all prescriptions up to 12 months before the
ndex date for adults (age 18 + ) were used, as in adults most ad-
erse events associated with PPI are linked to long-term usage. 16 
utcomes 
The primary outcomes were incidence of ReA and IBS within
2 months post-infection (PI). Secondary outcomes were the inci-
ence of CD, UC, RA and GBS and deaths where infection or se-
uelae is listed as a cause of death. Sequelae were identified using
ead codes in CPRD and ICD-10 codes in HES (Appendix Table S2,
2). Deaths within 12 months post-infection where any cause of
eath was Campylobacter , NTS, ReA, IBS, CD, UC, GBS and RA were
lso considered. 
All health service utilisation for primary (consultations, tests,
nd prescriptions) (Appendix Tables S3 – S4, p3-22) and secondary
ealthcare (hospital admissions, outpatients and colonoscopies) in
he five years before and after the index date were categorised to
nable attachment of unit costs. 
tatistical analyses 
Statistical analyses were performed in STATA version 14 (Stata
orporation, College Station, Texas, USA). Differences in the distri-
ution of exposures, covariates and outcomes were examined us-
ng t-tests and chi-squared tests, with 95% confidence intervals (CI)
nless otherwise stated. 
ncidence of sequelae 
In patients with Campylobacter or NTS, we estimated the inci-
ence of sequelae, expressed as a percentage and as a rate per
0 0 0 person-years (py) of follow-up, for up to 1, 3, 6 and 12
onths PI. 
isk factors associated with sequelae onset 
We performed logistic regression to assess the effect of antibi-
tics and PPI on the risk of sequelae onset following confirmed in-
ection with Campylobacter (there was insufficient power for NTS).
ntibiotic and PPI prescriptions were initially treated as binary.
hree multivariate model specifications were performed. Model 1
as used to adjust for age (continuous), sex, smoking status (none,
ormer or current), and CCI (0 vs 1 + ). Model 2 included age as cat-
gorical (18–24, 25–44, 45–64, 65 + ) to determine linearity in the
ffect of age. Model 3 included a categorisation of the total num-
er of PPI prescriptions (no PPI prescriptions; up to 5; 6–10; 10 + )
o assess a dose-response relationship. Interactions between pre-
ictors (PPI, age, sex, smoking status, and comorbidity) were also
ssessed. Counts less than five were not reported, to prevent de-
uctive disclosure. 
ealth service utilisation and costs 
We assessed the impact of the diagnosis of infection and se-
uelae on the average resource use and costs incurred by each pa-
ient. Using the cohort with a linked record in HES, we consideredPlease cite this article as: O.B. Esan, R. Perera and N. McCarthy et a
of campylobacter and non-typhoidal salmonella infections in England, 
health records, Journal of Infection, https://doi.org/10.1016/j.jinf.2020.05ll available data in the five years before and after the index date.
onsultations, tests, prescriptions, hospital admissions and outpa-
ient visits/procedures were reported as the average number of
vents per patient per quarter. We reported mean differences in
bserved resource use and costs between the periods before and
fter the index date alongside 95% CIs. Total costs per patient per
uarter were further stratified by sex, age, presence or absence
f comorbidities and SES. Mean estimates were compared using
tudent’s t -test. Quarterly costs per patient were further extrap-
lated to determine the expected overall costs to the NHS, with
rror propagation to account for uncertainty in the final estimates
7 (Appendix Box 1, p23). 
ole of the funding source 
The funder of the study had no role in study design, data col-
ection, data analysis, data interpretation, or writing of the report. 
esults 
tudy population 
Overall, 21,837 CPRD patients met the case definition
or Campylobacter (18,964) or NTS (2873), with linkage to
ES/ONS/IMD-2010 available for 17,108 (78%) ( Fig. 1 ). Charac-
eristics of patients without a linked record did not differ from
hose with linkage (Appendix Table S5). The onset of sequelae
as determined amongst 20,471 patients ( Campylobacter 17,838;
TS 2633) after excluding patients with a previous history of the
onditions of interest 1276 (6.2%) ( Fig. 1 ). 
ncidence of sequelae 
Table 1 shows the characteristics of patients with GII only (i.e.
ithout sequelae) and those who developed sequelae. The in-
idence of sequelae within 12 months PI was lower in Campy-
obacter patients, 1.5%, (274/17,838; 95%CI (1.4–1.7), than in NTS
atients, 2.8%, (73/2633); 95%CI (2.1–3.4). IBS was the most fre-
uently recorded sequela ( Campylobacte r patients, 74%, 203/274;
TS patients, 70%, 51/73), while ReA was higher amongst NTS pa-
ients (14%, 10/71) than Campylobacter patients (5%, 14/274). Seque-
ae patients were disproportionately likely to be females. 
The incidence of Campylobacter -associated ReA was highest in
he 1-month PI with a rapid decline subsequently ( Fig. 2 ). The rate
f onset of Campylobacter -associated IBS remained stable (12.2 per
0 0 0 py, 95%CI(10.6–13.9) at up to 12 months PI) and was lower
han NTS-associated IBS. The rate of NTS-associated IBS within 3
onths was approximately double that for Campylobacter (30.0 per
0 0 0 py, 95%CI (19.4–46.5) vs 14.6 per 10 0 0 py, 95%CI (11.4–18.6)).
eaths associated with sequelae 
Fewer than five deaths were recorded in the 12 months PI;
ence no further analysis was conducted to prevent deductive dis-
losure. 
isk factors associated with sequelae onset 
Campylobacter patients with sequelae who had a prescrip-
ion for antibiotics within seven days of the index date (38.4%,
05/274), mostly (68.6%, 72/105) had a prescription recorded on
he same day as their consultation for GII ( Table 1 ). Macrolides
ere the most frequently recorded (64.8%, 68/105) while only
ephalosporins was associated with an elevated risk of IBS (ad-
usted odds ratio [aOR] 3.6, 95%CI (1.1 – 11.7), P = 0.033) using the
redefined covariates (age, sex, CCI and smoking status ( Fig. 3 ). l., Incidence, risk factors, and health service burden of sequelae 
20 0 0–2015: A retrospective cohort study using linked electronic 
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Fig. 1. Fig. 1 shows the study population for the three main objectives based on the selection criteria. 
Fig. 2a. Fig. 2a shows the incidence of reactive arthritis following Campylobacter 
infection up to 12 months post-infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2b. Fig. 2b shows the incidence of irritable bowel syndrome following Campy- 
lobacter and NTS infection up to 12 months post-infection. 
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d  Amongst Campylobacter patients aged 18 and over with seque-
lae, 26% (4116/15,806) had a PPI prescription ( Table 1 ). PPI pre-
scription was associated with an elevated risk in the onset of IBS
(aOR 2.1, 95%CI 1.5–2.9, P < 0.001) ( Fig. 4 ). No effect was observed
for the secondary outcomes. Female sex influenced the elevated
risk of IBS in the multivariate analysis, while an increase in age
had a protective effect with a significant trend across all the age
groups (Model 1 and 2, Table 2 , Appendix Figure S1). 
When the total number of PPI prescriptions was used in place
of the presence or absence of PPI as the independent variable,
there was no significant trend in the risk of IBS with increased PPI
prescription within the year preceding infection (Model 3, Table 2 ).
There was also no evidence of any interaction with any of the co-
variates ( Table 3 ). 
Health service utilisation and costs 
Sequelae of Campylobacter and NTS infections resulted in in-
creased health service utilisation PI across all healthcare domainsPlease cite this article as: O.B. Esan, R. Perera and N. McCarthy et a
of campylobacter and non-typhoidal salmonella infections in England, 
health records, Journal of Infection, https://doi.org/10.1016/j.jinf.2020.05xcept for outpatients and hospital admissions in comparison with
atients with GII only. This costs an average of £331.0, (95%CI
£260.7, £401.4) and £211.0, (95%CI £58.8, £364.3) per patient
er quarter amongst Campylobacter and NTS patients respectively
 Table 4a ). Consequently, the additional annual costs of sequelae
f Campylobacter to the NHS was approximately £1.3 million (95%
.I £750,0 0 0, £1.7 million) for all patients who consulted their GP
or their infection in England. Correspondingly, for NTS infections,
 total cost of ∼£224,0 0 0 (95% C.I £0, £465,0 0 0) annually was in-
urred (Appendix Table S6). 
The difference in difference of the mean total costs in the pe-
iods’ pre-and post-infection was higher for males with sequelae
£510.2, 95%CI (£413.0, £607.3)) than for females (£183.9, 95%CI
£98.1, £269.7)). Although the overall costs of sequelae were higher
mongst patients aged 65 years and above (£603.5, 95%CI(£130.6,
859.4)) in comparison with younger age groups, there was a wide
ariation in the costs accrued by these patients due to the small
ample size of this group. 
Patients without sequelae living in the most affluent areas
IMD-1) accrued lower total costs PI than those living in the most
eprived areas (IMD-5) ( Table 5 ). For patients who developed se-l., Incidence, risk factors, and health service burden of sequelae 
20 0 0–2015: A retrospective cohort study using linked electronic 
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Table 1 
Characteristics of patients with Campylobacter and NTS infections with or without sequelae selected from CPRD with or without linkage to HES, 20 0 0–2015. 
Campylobacter Non-typhoidal Salmonella 
GII only, N = 17,564 Sequelae, N = 274 P-value GII only, N = 2560 Sequelae, N = 73 P -value 
Age (years), mean (Sd) 44.7 (21.2) 45.6 (17.2) 0.91 36.5 (23.3) 40.3 (17.2) 0.12 
Age group (years) 
0–4 911 (5.2) 0 (0.0) < 0.001 288 (10.9) † 0.002 
5–14 819 (4.7) 7 (2.6) 359 (13.5) 5 (6.8) 
15–24 1556 (8.9) 37 (13.5) 259 (9.8) 10 (13.7) 
25–44 5031 (28.6) 89 (32.5) 684 (25.8) 22 (30.1) 
45–64 5868 (33.4) 98 (35.8) 714 (26.9) 31 (42.5) 
65 + 3379 (19.2) 43 (15.7) 346 (13.1) †† 
Sex 
Male 9455 (53.8) 99 (36.1) < 0.001 1307 (49.3) 28 (38.4) 0.06 
Female 8109 (46.2) 175 (63.9) 1343 (50.7) 45 (61.6) 
Index of multiple deprivation 
1 4119 (23.5) 71 (25.9) 0.44 570 (21.5) 17 (23.3) 0.65 
2 3565 (20.3) 62 (22.6) 479 (18.7) 16 (21.9) 
3 2710 (15.4) 35 (12.7) 423 (16.5) 13 (17.8) 
4 2076 (11.8) 32 (11.7) 352 (13.8) † 
5 1268 (7.2) 15 (5.5) 233 (9.1) † 
missing 3826 (21.8) 59 (21.5) 503 (19.6) 16 (21.9) 
Smoking status 
Ever smoked 5197 (29.6) 79(28.8) 0.18 712 (26.9) 19 (26.0) 0.66 
Never smoked 11,152 (63.5) 167 (60.9) 1787 (67.4) 48 (65.8) 
Missing 1215 (6.9) 28 (10.2) 151 (5.7) 6 (8.2) 
Comorbidities 
None 174 (63.5) 11,526 (65.6) 0.46 1928 (72.8) 51 (69.9) 0.58 
1 or more 100 (36.5) 6038 (34.4) 722 (27.2) 22 (30.1) 
Antibiotics 
Yes 6395 (36.4) 105 (38.3) 0.52 737 (27.8) 24 (32.9) 0.34 
Antibiotics Class 
Macrolides 3726 (58.3) 68 (64.8) 0.078 50 (1.9) 1 (1.4) 0.61 
Quinolones 2606 (40.8) 34 (12.4) 672 (25.4) 23 (31.5) 
Cephalosporins 63 (1.0) † 15 (0.6) 0 (0.0) 
Antibiotics R x Day 
∗
1–7 before 766 (12.0) 13 (4.7) 0.93 100 (3.8) 7 (9.6) 0.038 
0 4375 (68.4) 72 (68.6) 461 (17.4) 15 (20.5) 
1–7 after 1256 (19.6) 20 (19.0) 176 (6.6) † 
No 11,167 (63.6) 169 (61.7) 1913 (72.2) 49 (67.1) 
PPI ‡ 
Yes 4027 (25.9) 89 (33.5) 0.005 394 (20.3) 16 (24.6) 0.4 
No 11,517 (74.1) 177 (66.5) 1545 (79.7) 49 (75.4) 
Hospitalised 
No 17,027 (96.9) 266 (97.1) 0.9 2514 (94.9) 68 (93.2) 0.51 
Yes 537 (3.1) 8 (2.9) 136 (5.1) 5 (6.8) 
Sequelae 
ReA – 14 (5.1) – 10 (13.7) 
IBS – 203 (74.1) – 51 (69.9) 
UC – 28 (10.2) – †† 
CD – 10 (3.6) – 7 (9.6) 
RA – 11 (4.0) – † 
GBS – 8 (2.9) – 0 
sd – Standard deviation; Hospitalised- Patients hospitalised within 30 days of GII in CPRD; † events less than 5 reduce deductive disclosure in accordance with the protocol; 
†† events suppressed to prevent deductive disclosure of figures in the table; ∗Antibiotics Rx Day – Day of prescription of antibiotics in the 7 days before or after consultation 
for GII, where 0 is the day of consultation 
‡ PPI only considered amongst patients aged 18 and over, n = 15,806. 
Fig. 3. Fig. 3 shows the logistic regression model for the association of three classes of antibiotics (macrolides, quinolones and cephalosporins) and the onset of irritable 
bowel syndrome up to 12 months following Campylobacter infection. 
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Fig. 4. Fig. 4 shows the logistic regression model for the association of prescription of proton pump inhibitors within 12 months before Campylobacter infection and the 
onset of reactive arthritis, irritable bowel syndrome, ulcerative colitis and rheumatoid arthritis following Campylobacter infection. 
Table 2 
Summary of logistic regression model to assess the relationship between prescrip- 
tion of PPI and the onset of IBS following Campylobacter infection. 
Patients included in each model, n = 15,806 
Model Factor aOR ‡ IBS 1 [95% C.I] P- value 
Model 1 PPI 2.1 1.5 2.9 < 0.001 
Age 0.97 0.96 0.98 < 0.001 
Sex 
Males Referent 
Females 2.5 1.9 3.4 < 0.001 
Smoking status 
Non-smokers/missing Referent 
Current 0.9 0.4 1.9 0.776 
Ex-smokers 0.9 0.3 2.8 0.741 
Comorbidity 
None Referent 
1 or more 1.3 0.5 0.7 2.35 
PPI 2.1 1.5 2.9 < 0.001 
Model 2 Age 
18–24 Referent 
25–44 0.5 0.3 0.8 0.003 
45–64 0.4 0.3 0.6 < 0.001 
65 + 0.2 0.1 0.4 < 0.001 
Sex 
Males Referent 
Females 2.5 1.9 3.4 < 0.001 
Smoking status 
Non-smokers/missing Referent 
Current 0.9 0.4 1.9 0.776 
Ex-smokers 0.9 0.3 2.8 0.741 
Comorbidity 
None Referent 
1 or more 0.9 0.7 1.3 0.716 
Model 3 Total PPI 
0 Referent 
1–5 2.1 1.4 3 < 0.001 
5–10 2 1.2 3.3 0.01 
> 10 2.5 1.4 4.4 < 0.001 
Age 0.97 0.96 0.98 < 0.001 
Sex 
Males Referent 
Females 2.5 1.9 3.4 < 0.001 
Smoking status 
Non-smokers/missing Referent 
Current 0.8 0.6 1.2 0.264 
Ex-smokers 1.1 0.7 1.9 0.660 
Comorbidity 
None Referent 
1 or more 0.9 0.7 1.3 0.724 
Abbreviations and symbols: ‡ Adjusted odds ratio (adjusted for age, sex, smoking 
status and CCI); IBS 1 - 197 patients developed IBS; 95% Confidence Interval; P -value 
likelihood ratio test; 2 - time of onset post-infection. 
Table 3 
Interaction terms for multivariable logistic regression to assess relation between 
prescription of PPI and the onset of IBS following Campylobacter infection. 
Factor OR ‡ [95% C.I] P -Value 
PPI 
No Referent 
Yes 2.9 0.9 8.7 0.063 
Sex 
Male Referent 
Female 2.5 1.2 5.6 0.02 
Agegrp 
18–24 Referent 
25–44 0.7 0.3 1.6 0.424 
45–64 0.4 0.2 0.9 0.02 
65 + 0.2 0.1 0.6 0.007 
Smoking 
Missing/None Referent 
Current 0.9 0.4 1.6 0.579 
Ex-smokers 1.1 0.5 2.5 0.856 
CCI 
None Referent 
1 or more 0.9 0.6 1.3 0.448 
Interactions 
PPI#Sex 
Yes#Female 1.1 0.5 2.3 0.768 
PPI#Agegrp 
Yes#25–44 0.6 0.2 1.9 0.359 
Yes#45–64 0.6 0.2 1.8 0.343 
Yes#65 + 0.9 0.2 3.2 0.822 
Sex#Agegrp 
Female#25–44 0.7 0.3 1.7 0.443 
Female#45–64 1.3 0.5 3.5 0.557 
Female#65 + 0.9 0.2 3.0 0.808 
PPI#Smoking 
Yes#Current 1.3 0.4 1.8 0.64 
Yes #Ex-smoker 0.8 0.3 5.4 0.644 
PPI#CCI 
1 or more 1.3 0.7 2.5 0.441 
Abbreviations and symbols: ‡ Odds ratio; 95% Confidence Interval; P -value likelihood 
ratio test. 
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Table 4a 
Average quarterly healthcare utilisation amongst patients with Campylobacter or NTS infection (with or without sequelae) in the quarters preceding and after infection in England, 20 0 0–2015. 
Resource use for patients with Campylobacter infection 
Category GII only GII with sequelae Impact of sequelae 
After (A) 1 Before (B) 1 Difference (A-B) 2 After (A) 1 Before (B) 1 Difference (A-B) 2 After 3 Before 4 DID 
Consultations 1.9 (0.02) 2.1 (0.02) −0.3 ( −0.3 −0.2) ∗ 3.3 (0.2) 2.8 (0.1) 0.5 (0.04, 1.0) ∗ 1.4 (1.2, 1.7) ∗∗ 0.7 (0.4, 0.9) ∗∗ 0.8 (0.6, 1.0) ∗∗
Prescriptions 5.3 (0.08) 5.4 (0.08) −0.06 ( −0.3, 0.2) 7.3 (0.6) 6.1 (0.5) 1.2 ( −0.3, 2.7) 2.0 (0.8, 3.3) ∗ 0.73 ( −0.5, 1.9) 1.3 (0.8, 1.8) ∗∗
Tests 1.6 (0.02) 1.9 (0.02) −0.3 ( −0.4, −0.2) ∗ 3.6 (0.3) 2.5 (0.2) 1.1 (0.4, 1.8) ∗ 2.0 (1.6, 2.4) ∗ 0.6 (0.3, 1.0) ∗∗ 1.4 (1.1, 1.7) ∗∗
Outpatients 0.04 (0.002) 0.04 (0.002) 0.006 (0.001, 0.01) ∗ 0.09 (0.02) 0.08 (0.02) 0.01 ( −0.06, 0.08) 0.05 (0.0, 0.1) ∗ 0.05 (0.02, 0.1) ∗∗ 0.004 ( −0.03, 0.04) 
Admissions 0.1 (0.002) 0.09 (0.003) 0.0003 ( −0.007, 0.007) 0.3 (0.06) 0.10 (0.02) 0.2 (0.03, 0.3) ∗ 0.17 (0.1, 0.2) ∗∗ 0.007 ( −0.03, 0.1) 0.2 (0.1, 0.2) ∗∗
Colonoscopy 0.003 (0.002) 0.002 (0.0002) 0.0009 (0.0003, 0.002) ∗ 0.02 (0.005) 0.003 (0.002) 0.02 (0.01, 0.03) ∗ 0.02 (0.02, 0.02) ∗∗ 0.0009 ( −0.002, 0.004) 0.02 (0.02, 0.03) ∗∗
Resource use for patients with NTS infection 
Consultations 1.8 (0.04) 2.0 (0.04) −0.2 ( −0.3, −0.03) ∗ 3.4 (0.4) 2.5 (0.2) 0.9 (0.1, 1.8) ∗ 1.6 (1.1, 2.2) ∗∗ 0.5 (0.03, 1.0) ∗ 1.1 (0.7, 1.5) ∗∗
Prescriptions 4.0 (0.2) 4 0.1(0.2) −0.1 ( −0.6, 0.4) 6.7 (1.3) 4.8 (0.9) 1.9 ( −1.2, 5.0) 2.7 (0.6, 4.8) ∗ 0.7 ( −1.4, 2.9) 2.0 (0.8, 3.2) ∗
Tests 1.4 (0.05) 1.4 (0.05) −0.02 ( −0.2, 0.1) 2.9 (0.5) 1.8 (0.3) 1.1 (0.004, 2.2) 1.5 (0.9, 2.1) ∗∗ 0.4 ( −0.2, 0.9) 1.1 (0.6, 1.7) ∗∗
Outpatients 0.03 (0.005) 0.02 (0.003) 0.005 ( −0.006, 0.02) 0.07 (0.03) 0.1 (0.03) 0.004 ( −0.08, 0.08) 0.04 ( −0.02, 0.1) 0.04 (0.007, 0.07) ∗ −0.001 ( −0.06, 0.06) 
Admissions 0.1 (0.02) 0.1 (0.02) −0.1 ( −0.06, 0.04) 0.2 (0.04) 0.1 (0.03) 0.08 ( −0.004, 0.2) 0.07 ( −0.2, 0.3) −0.2( −0.3, 0.2) 0.09 (0.02, 0.2) ∗
Colonoscopy 0.003 (0.0006) 0.002 (0.0005) 0.001 ( −0.0004, 0.002) 0.02 (0.009) 0.004 (0.004) 0.01 ( −0.006, 0.03) 0.01 (0.008, 0.02) ∗∗ −0.003( −0.003, 0.009) 0.01 (0.003, 0.02) ∗
1 Standard error in parentheses. 
2 95% Confidence interval in parentheses; After 3 (mean quarterly utilisation rate in the periods after infection for patients with selected GII and sequelae – mean quarterly utilisation rate in the periods after infection for 
patients with GII only) Before 4 -(mean quarterly utilisation rate in the periods before infection for patients with GII and sequelae – -(mean quarterly utilisation rate in the periods before infection for patients with selected GII 
only); DID – Difference in mean differences (After 3 – Before 4 ); ∗Independent Student’s t -test P -value < 0.05; ∗∗Independent Student’s t -test P -value < 0.01. 
Table 4b 
Average quarterly healthcare costs amongst patients with Campylobacter or NTS infection (with or without sequelae) in the quarters preceding and after infection in England, 20 0 0–2015. 
Healthcare costs accrued by patients with Campylobacter infection 
GII only GII with sequelae Impact of sequelae 
Category After (A) 1 Before (B) 1 Difference (A-B) 2 After (A) 1 Before (B) 1 Difference (A-B) 2 After 3 Before 4 DID 
Consultations 47.8(0.5) 56.4 (0.5) −8.6 ( −10.0, −7.3) ∗ 85.4 (4.8) 74.5 (4.5) −10.8 ( −2.1, 23.7) 37.6 (30.1, 45.2) ∗∗ 18.2 (10.7, 25.6) ∗∗ 19.5 (13.4, 25.6) ∗∗
Prescriptions 44.0 (0.7) 44.5(0.5) −0.5 ( −2.4, 1.4) 68.6 (5.7) 53.9 (5.1) 14.7 ( −0.3, 29.7) 24.6 (13.7, 35.6) ∗∗ 9.4 ( −1.1, 19.9) 14.7 (13.9, 15.6) ∗∗
Tests 12.5 (0.2) 10.7 (0.17) −1.8 ( −2.3, −1.4) ∗ 22.7 (2.2) 18.1 (1.6) 4.6 ( −0.7, 9.8) 12.0 (£9.3, 14.6) ∗∗ 5.6 (3.1, 8.06) ∗∗ 6.4 (3.6, 9.3) ∗∗
Outpatients 3.8 (0.3) 3.04 (0.20) 0.7 (0.1, 1.4) ∗ 17.01 (8.4) 12.3 (6.6) 4.76 ( −16.3, 25.8) 13.2 (8.8, 17.7) ∗∗ 9.2 (5.6, 12.8) ∗∗ 4.0 ( −0.3, 8.4) 
Admissions 105.7 (3.5) 115.4 (3.4) −9.7 ( −19.3, −0.1) 380.5 (84.0) 114.7 (24.7) 265.8 (93.8, 437.7) ∗ 274.8 (216.4, 333.3) ∗∗ −0.6 ( −54.6, 53.4) 275.5 (208.5, 342.4) ∗∗
Colonoscopy 1.7 (0.1) 1.2 (0.1) 0.5 (0.2, 0.8) ∗ 12.6 (2.4) 1.6 (0.9) 11.0 (5.6, 16.4) ∗ 10.9 (8.8, 12.9) ∗∗ 0.4 ( −1.2, 2.0) 10.4 (7.4, 13.0) ∗∗
Total 213.6 (4.0) 233.0 (2.8) −19.4 ( −30.4, −8.4) ∗ 586.7 (88.5) 75.1 (31.1) 311.6 (127.3, 495.9) ∗ 373.2 (304.5, 439.8) ∗∗ 42.1 ( −20.0, 104.3) 331.0 (260.7, 401.4) ∗∗
Healthcare costs accrued by patients with NTS infection 
Consultations 48.1 (1.2) 53.6 (1.1) −5.5 ( −8.7, −2.3) ∗∗ 89.6 (9.2) 70.2 (7.6) 19.4 ( −4.2, 43.1) 41.5 (26.9, 56.2) ∗∗ 16.6 (2.9, 30.3) ∗ £25.0 (£12.4, £37.5) ∗∗
Prescriptions 35.3 (1.5) 35.8 (1.5) −0.5 ( −4.8, 3.7) 63.0 (9.7) 42.3 (7.9) 20.8 ( −8.8, 50.4) 27.8 (8.7, 46.9) ∗ 6.50 ( −12.2, 25.2) 20.8 (18.5, 23.2) ∗∗
Tests 9.7 (0.4) 10.1 (0.4) −0.4 ( −1.5, 0.6) 20.9 (4.0) 11.2 (2.1) 9.7 (0.7, 18.7) ∗ 11.2 (6.6, 15.9) ∗∗ 1.1 ( −3.6, 5.9) 10.1 (4.8, 15.4) ∗
Outpatients 2.6 (1.0) 1.7 (0.2) 0.9 ( −1.2, −3.0) 5.3 (2.2) 5.5 (2.5) −0.24 ( −6.8, 6.3) 2.7 ( −9.9, 15.2) 3.8 (0.8, 6.9) ∗ −1.2 ( −12.3, 9.5) 
Admissions 101.6 (10.1) 122.9 (9.3) −21.3 ( −48.2, 5.7) 198.1 (56.9) 68.6 (25.2) 129.6 (6.4, 252.8) ∗ 96.5 ( −27.1, 220.2) −54.3 ( −167.9, 59.3) 150. 8 (2.4, 299.3) 
Colonoscopy 1.3 (0.3) 0.8 (0.2) 0.5 ( −0.2, 1.2) 8.7 (4.3) 2.6 (2.632) 6.1 ( −3.8, 16.0) 7.4 (3.7, 11.0) ∗∗ 1.8 ( −1.1, 4.7) 5.5 (0.9, 10.2) ∗
Total 198.6 (11.2) 224.9 (10.4) −26.5 ( −56.1, 3.6) 385.7 (69.9) 200.4 (35.0) 185.3 (30.4, 340.2) ∗ 187.1 (49.8, 324.4) ∗ −24.5 ( −150.7, 101.8) 211.5 (58.8, 364.3) ∗
All figures in £. 
1 Standard error in parentheses. 
2 95% Confidence interval in parentheses; After 3 (mean quarterly costs in the periods after infection for patients with GII and sequelae – mean quarterly costs in the periods after infection for patients with GII only) Before 4 - 
(mean quarterly costs in the periods before infection for patients with GII and sequelae – (mean quarterly costs in the periods before infection for patients with GII infection only); DID – Difference in mean differences (After 3 –
Before 4 ); ∗Independent Student’s t -test P -value < 0.05; ∗∗Independent Student’s t -test P -value < 0.01. 
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Table 5 
Total costs per patient by sex, age group and deprivation quintiles for patients with Campylobacter and NTS GII with or without sequelae in England, 20 0 0–2015. 
Patients with GII only ( N = 16,822) Patients with GII and sequelae ( N = 286) Impact of sequelae 
Stratum After Before (B) 
Difference 
(A-B) Stratum After Before 
Difference 
(A-B) After 1 Before 2 DID 3 
Males (n = 8755) 202.1 (192.4, 
211.9) 
253.3 (243.7, 
263.0) 
−51.2 ( −64.9, 
−37.5) ∗∗
n = 107 710.4 (400.4, 
1020.3) 
238.4 (158.2, 
318.6) 
472.0 (153.6, 
790.3) ∗
481.0(388.0, 
573.9) ∗∗
−29.2 ( −114.5, 
56.1) 
510.2 (413.0, 
607.3) ∗∗
Females (n = 8067) 254.0 (242.5, 
265.5) 
301.9 (290.6, 
313.2) 
−47.9 ( −64 
−31.8) ∗∗
n = 179 497.2 (361.1, 
633.3) 
363.7 (295.9, 
431.5) 
133.5 ( −18.0, 
285.0) 
235.4 (156.0, 
314.8) ∗∗
51.5 ( −23.3 
126.3) 
183.9 (98.1 
269.7) ∗∗
0–17 yrs (n = 2269) 99.6 (91.4, 
107.9) 
164.9 (150.8, 
179.0) 
−65.3 ( −81.6, 
−49) ∗∗
n = 15 284.3 (114.8, 
453.8) 
156.4 (92.9, 
220.0) 
127.9 ( −45, 
300.7) 
146.3 (49.1, 
243.4) ∗
−43.9 ( −214.6, 
126.7) 
190.2 (22.5, 
357.9) ∗
18–44 yrs (n = 6186) 151.8 (141.9, 
161.6) 
198.0 (188.3, 
207.8) 
−46.3 ( −60.1, 
−32.4) ∗∗
n = 128 323.9 (244.7, 
403.0) 
216.9 (166.3, 
267.6) 
106.9 (13.4, 
200.4) ∗
159.1 (89.6, 
228.6) ∗∗
14.8 ( −52, 
81.6) 
144.3 (71.5, 
217.1) ∗∗
45–64 yrs (n = 4999) 226.8 (214.2, 
239.4) 
271.5 (259.7, 
283.3) 
−44.7 ( −62, 
−27.4) ∗∗
n = 96 669.4 (338.5, 
1000.2) 
295.7 (228, 
363.5) 
373.6 (38.1, 
709.2) ∗
421.6 (321.1, 
522.2) ∗∗
7 ( −76.5, 90.5) 414.7 (307.4, 
521.9) ∗∗
65 yrs + (n = 3093) 477.2 (450.6, 
503.8) 
529.3 (503.9, 
554.8) 
−52.1 ( −89, 
−15.3) ∗∗
n = 43 1248.6 (726.9, 
1770.3) 
705.9 (459.3, 
952.4) 
542.7 ( −25.9, 
1111.3) 
768.8 (537.5, 
1000) ∗∗
165.4 ( −47.7, 
378.6) 
603.4 (347.4, 
859.4) ∗∗
IMD - Q1 (n = 4973) 199.7 (187.5, 
211.8) 
239.1 (227.4, 
250.9) 
−39.5 ( −56.4, 
−22.6) ∗∗
n = 91 369.2 (206.0, 
532.4) 
295.2 (199.4, 
391) 
74 ( −114, 262) 165.9 (75.3, 
256.5) ∗∗
45.9 ( −39.5, 
131.3) 
120.0 (19.7, 
220.3) ∗
IMD - Q2 (n = 4335) 217.5 (203.6, 
231.4) 
266 (252.1, 
279.9) 
−48.4 ( −68.1, 
−28.8) ∗∗
n = 84 780.7 (398.6, 
1162.9) 
390.7 (268.8, 
512.5) 
390.1 ( −8.1, 
788.3) 
541.1 (429.9, 
652.4) ∗∗
97.5 ( −1.4, 
196.3) 
443.7 (327.2, 
560.2) ∗∗
IMD - Q3 (n = 3335) 240.9 (222.5, 
259.3) 
300.3 (281.5, 
319.0) 
−59.3 ( −85.6, 
−33.1) ∗∗
n = 49 458.1 (297.3, 
618.9) 
212.4 (147.9, 
276.9) 
245.7 (74.7, 
416.8) ∗
189.0 (37.3, 
340.7) ∗
−77.6 ( −228.6, 
73.4) 
266.6 (107, 
426.3) ∗
IMD - Q4 (n = 2585) 233 (215.4, 
250.5) 
285.1 (268.2, 
302.1) 
-£52.2 ( −76.5, 
−27.8) ∗∗
n = 41 676.9 (409.4, 
944.5) 
347.5 (213.8, 
481.2) 
329.5 (35, 
624) ∗
420.1 (277.5, 
562.7) ∗∗
74 ( −58.1, 
206.2) 
346.1 (193.7, 
498.4) ∗∗
IMD - Q5 (n = 1582) 299.2 (266, 
332.3) 
359.1 (327.3, 
390.9) 
−59.9 ( −105.8, 
−14.0) ∗∗
n = 20 776.6 ( −93.9, 
1647.1) 
295.8 (172.5, 
419) 
480.9 ( −369.5, 
1331.2) 
495.2 (185.7, 
804.7) ∗
−118.8 
( −395.8, 158.2) 
614.0 (287.6, 
940.3) ∗∗
CCI - no ( n = 11,150) 136.5 (129.8, 
143.2) 
148.1 (142.3, 
153.9) 
−11.6 ( −20.5, 
−2.7) ∗
n = 183 297.6 (215.4, 
379.8) 
147.6 (118.8, 
176.3) 
150.0 (63.2, 
236.9) ∗∗
161.1 (107.7, 
214.5) ∗∗
−0.5 ( −46.2, 
45.1) 
161.6 (104.2, 
219) ∗∗
CCI - yes ( n = 5672) 359.3 (342.3, 
376.3) 
396.8 (379.5, 
414.0) 
−37.5 ( −61.7, 
−13.2) ∗
n = 103 989.2 (634, 
1344.3) 
460.4 (336.1, 
584.7) 
528.8 (154.7, 
902.8) ∗∗
629.9 (495.2, 
764.5) ∗∗
63.6 ( −65.7, 
192.9) 
566.2 (418.6, 
713.9) ∗∗
All figures in £; ∗P < 0.05; ∗∗P < 0.001; After 1 – (Mean cost quarters after infection for patients with GII and sequelae – Mean cost quarters after infection for patients with GII only) Before 2 -(Mean cost quarters before infection for 
patients with GII and sequelae – Mean cost quarters before infection for patients with GII only); DID 3 – Difference in mean differences (After 1 - Before 2 ); IMD – Index of Multiple Deprivation; Q – Quintile, Q1 – Least deprived, 
Q5 – Most deprived; CCI – Charlson comorbidity index. 
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q  osed. Female Campylobacter patients under 65 years of age with
 prescription for PPI up to a year preceding infection were more
ikely to develop IBS. Those with a cephalosporin prescription in
he seven days before/after infection also had a moderate elevated
isk for the onset of IBS. Although the incidence of sequelae was
ow, the impact on the NHS was significant. Overall, the sequelae
f Campylobacter infection led to an estimated £1.3 million in ad-
itional annual NHS healthcare expenditure in England, while se-
uelae of NTS infection produced a lower but substantial total cost
f ∼£224,0 0 0 (95% C.I £0, £460,0 0 0) annually. 
The proportion of patients with a recorded diagnosis for IBS fol-
owing Campylobacter (1.1%) or NTS (1.9%) in our study was higher
han published estimates by Ternhag and colleagues using histor-
cal medical records ( Campylobacter , 0.03–0.89%; NTS, 0.01–1%). 18 
ur study incorporated outcomes from both primary and sec-
ndary care, while the earlier study only used hospital discharge
ecords to determine sequelae. Thus, conditions commonly diag-
osed in primary care settings, such as IBS, may have been under-
eported previously. In keeping with similar studies assessing the
ncidence of IBS within 12 months of Campylobacter infection, the
ate of IBS following Campylobacter infection was ∼ 6-fold higher
han the reported incidence of IBS in the absence of GII ( ∼ two per
0 0 0 person-years). 19 The incidence of the secondary outcomes
as low. Similar to other studies, we did not find evidence of GBS
ollowing NTS infection. 6 
The elevated risk of IBS following PPI prescription was mainly
riven by females of a younger age in the cohort ( < 65 years old).
he elevated risk reflects their overall increased propensity for the
evelopment of IBS symptoms regardless of a PPI prescription as
here was no evidence of interactions. Many functional disorders in
emales may be attributed to gender-specific factors such as circu-
ating sex hormones and changes in rectal sensitivity during men-
trual cycles. Increased prevalence of psychological symptoms of
nxiety, depression and somatisation in females may also be mod-
fiable factors associated with IBS. 20 Infection may trigger initial
ymptoms, while cognition, behaviour and emotions may prolong
nd maintain them over time. 4 
Only prescriptions for cephalosporin was associated with the
nset of IBS in our study. A systematic review assessing the factors
ssociated with the prevalence of PI-IBS also reported an elevated
isk following treatment with antibiotics but did not specify the
lass of antibiotics, age group or the pathogen-specific risk esti-
ates; while another only identified a study with increased risk in
hildren only. 20 , 21 Current guidelines recommend clarithromycin,
 macrolide for Campylobacter infection for returning travellers
the main indication for treatment, and not cephalosporin, a
road-spectrum antibiotic linked to increased risk of Clostrid-
um difficile . 22 The observed association with antibiotics should
e interpreted with caution as only a small number of patients
ere prescribed cephalosporins and the significant result may
e have arisen due to multiciplicity of testing in the regression
odel. 
We did not find an association between the onset of any of
he secondary outcomes and the prescriptions considered and it
as not possible to examine some of them (GBS and CD). This
s in contrast to a recent case-control study which found an in-
reased odds of inflammatory bowel disease (aOR 1.6, 95% C.I 1.6–
.7) following antecedent GII with an elevated odds for antimicro-
ial treatment (aOR 4.16, 95% C.I 3.3–5.3), although treatment was
are amongst cases (1.5%) and CD or UC were not considered sep-
rately. 21 
Stratification of resource use and costs by patient age, sex and
CI shows that patients aged 65 and over, males, and those with
xisting comorbidities who developed sequelae incurred the high-
st cost PI. Older age and living with comorbidities are common
atient characteristics linked to increased healthcare utilisationPlease cite this article as: O.B. Esan, R. Perera and N. McCarthy et a
of campylobacter and non-typhoidal salmonella infections in England, 
health records, Journal of Infection, https://doi.org/10.1016/j.jinf.2020.05nd costs. 23 However, the patient groups which accrued the high-
st costs were not the same group of patients at risk of developing
BS following Campylobacter infection (younger females, < 65). Con-
equently, the health service needs of patients at risk of sequelae
ay be masked by the healthcare usage of those with a propensity
o access healthcare, such as older patients and those with existing
omorbidities. 
On average, approximately £330 extra in expenditure is in-
urred per quarter for every case of Campylobacter with sequelae.
ublished studies in the UK, the Netherlands and Australia sug-
est Campylobacter patients incur more costs than NTS patients,
ith direct healthcare costs accounting for 20–24% of total costs
ncurred. 24–26 The remaining 76–80% of total costs incurred were
ndirect non-healthcare related costs such as productivity losses. 
Our study has several strengths. It uses patient-linked records
cross all the major healthcare access points in England. Database
inkage allowed analysis of the temporal association between
athogen-specific diagnosis and sequelae onset and also limited
he misclassification of prevalent cases as incident cases. The large
ize of the cohort increased the level of precision in estimating the
ncidence of rare outcomes and associated risk factors, with up-
ated estimates on direct healthcare costs of sequelae. 
Our estimates are generalisable to the population of England
ho consult for GII, as CPRD is a nationally representative data
ource. Community level estimates of sequelae of GII may be
xtrapolated with caution using ascertainment ratios from IID2
hich measure the level of underreporting of IID amongst those
ho present to healthcare and the level in the community. 2 
his is because such extrapolated estimates may require correc-
ion/adjustment for differential rate in the incidence of sequelae
mongst confirmed and undiagnosed cases of Campylobacter or
TS infections. Confirmed cases of these GII may have a higher rate
f sequelae than undiagnosed cases, leading to an overestimate of
ncidence of sequelae following these GII in the community. 
Our study also has some limitations. Eligibility was based on
ead codes following consultation for Campylobacter or NTS infec-
ions, which requires patients to have had a confirmed diagnosis
rom stool culture. Requests for stool culture may vary by GP, and
hen stool culture is requested, results may not be systematically
ecorded. 27 , 28 This may have introduced selection bias, as GPs are
ore likely to request a stool culture for patients who report for-
ign travel or have severe symptoms such as bloody or prolonged
iarrhoea. 27 , 28 It was not possible to stratify patients by symp- 
om severity, as this is usually recorded within a free-text field not
vailable to researchers. 
We did not include other possible indications for PPI prescrip-
ion in the regression model. Only the CCI was used as a mea-
ure of pre-existing conditions, and this did not influence the risk
stimates. Further, we did not assess the length of PPI exposure
nd PPI dose. We did not include prescription of less potent acid-
educing drugs such as H2-receptor antagonist in the regression
odel following previous studies showing a stronger association
ith PPI and onset of adverse events. 29 
The cost estimates in our study are from a payer’s perspective
nd do not include direct estimation of costs borne by individuals,
uch as out-of-pocket expenses resulting from illness or societal
osts from illness in patients and caregivers which include costs of
ost productivity to patients/employers. This is beyond the scope of
ur study and presents an avenue for further research. 
In summary, the incidence of sequelae of Campylobacter and
TS is low, but with a significant additional burden on health-
are resources, most notably amongst those who frequently ac-
ess healthcare (older people and those with existing comorbidi-
ies). These heavy users were different from those at risk of se-
uelae such as IBS following Campylobacter infection who were fe-l., Incidence, risk factors, and health service burden of sequelae 
20 0 0–2015: A retrospective cohort study using linked electronic 
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2  
 males below the age of 65 years. The estimates from our study
provide substantial baseline data in understanding the burden of
these GII. These pathogen-specific estimates can be incorporated
into the burden of disease studies to inform prevention strategies. 
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